

Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market Growth 2026-2032

<https://marketpublishers.com/r/GE3A0A7E0374EN.html>

Date: October 2026

Pages: 92

Price: US\$ 3,660.00 (Single User License)

ID: GE3A0A7E0374EN

Abstracts

The global HIV Early Infant Diagnosis Molecular Diagnostic Tests market size is predicted to grow from US\$ 20.64 million in 2025 to US\$ 27.00 million in 2032; it is expected to grow at a CAGR of 4.3% from 2026 to 2032.

HIV Early Infant Diagnosis Molecular Diagnostic Tests are in vitro diagnostic nucleic acid tests designed for direct virological detection of HIV infection in HIV-exposed infants, principally children younger than 18 months for whom persistent maternal antibodies limit the diagnostic value of conventional serology. The market covers integrated single-test cartridges, automated analyzer reagent kits and conventional PCR reagent kits that detect HIV DNA, HIV RNA or total HIV nucleic acids through PCR-based NAT, transcription-mediated amplification or other validated molecular amplification technologies. Depending on the platform, specimens may include whole blood, dried blood spots, plasma or serum, with results generally reported qualitatively and, for appropriately validated assays, quantitatively. The products support birth NAT testing, routine initial early infant diagnosis, scheduled repeat testing, confirmatory NAT following an initial positive result and additional testing associated with ongoing breastfeeding exposure. The research focus is the recurring molecular diagnostic reagent and test-consumable component used within early infant diagnosis workflows. WHO continues to define nucleic acid testing as the required virological approach for HIV diagnosis in exposed infants younger than 18 months.

Key Findings

Sub-Saharan Africa remains the principal demand center, while early infant diagnosis coverage varies materially between African subregions

Integrated cartridges, automated analyzer reagents and conventional PCR kits form the three principal product configurations

Nine core manufacturers are identified, with competition concentrated among a limited number of multinational and specialist molecular diagnostics suppliers

Market Trends

HIV Early Infant Diagnosis Molecular Diagnostic Tests are developing along two parallel paths. Centralized laboratories continue to rely on high-throughput automated platforms because they can consolidate HIV EID with other molecular testing workloads, while decentralized programs increasingly favor integrated molecular cartridges capable of processing whole blood or dried blood spot specimens closer to maternity, pediatric and primary-care settings. The technology direction is therefore moving toward shorter workflows, lower sample-handling requirements, automated interpretation and improved access outside major laboratories rather than toward a single universal platform architecture. Cepheid currently positions Xpert HIV-1 Qual XC as a molecular point-of-care assay delivering results in around 90 minutes, while Roche continues to support automated qualitative NAT on its cobas high-throughput platforms.

Market Dynamics

Drivers

Demand is underpinned by the clinical requirement for virological diagnosis before 18 months of age, when maternal HIV antibodies can interfere with serological diagnosis, and by the need to initiate antiretroviral therapy rapidly in infected infants. WHO recommends testing HIV-exposed infants by two months of age and continued testing during and after breastfeeding exposure, creating recurring demand rather than a single-test pathway. Expansion of birth testing, routine EID programs, repeat NAT and decentralized point-of-care testing supports reagent consumption across both centralized and peripheral healthcare networks.

Restraints

The principal constraints are program financing, uneven access to molecular laboratories, sample-referral delays, procurement volatility and the higher unit cost of decentralized molecular tests compared with high-throughput centralized assays. The gradual reduction in mother-to-child HIV transmission also limits the underlying pool of

infected infants, while falling positivity increases the importance of highly specific confirmatory algorithms. Funding disruptions can translate quickly into lower testing activity because a substantial share of EID demand is embedded in nationally coordinated and donor-supported HIV programs rather than conventional private-pay diagnostic markets. UNAIDS reported that early infant diagnosis coverage and pediatric HIV services deteriorated in several sub-Saharan African countries following funding reductions in 2025.

Opportunities

The largest structural opportunity lies in closing testing gaps rather than expanding the addressable population itself. Wider deployment of point-of-care NAT can shorten the interval between specimen collection, result return and treatment initiation, particularly where centralized sample transport produces long turnaround times. Additional opportunities arise from birth NAT for higher-risk newborns, systematic repeat testing during the exposure period, breastfeeding-related additional NAT and improved integration of EID into broader molecular diagnostic platforms. WHO guidance explicitly supports point-of-care NAT for both initial diagnosis and confirmation of positive results.

Challenges

Long-term market development requires balancing affordability with the economics of maintaining sophisticated molecular platforms in relatively low-volume pediatric testing programs. Manufacturers must sustain reagent availability, lot-to-lot performance, genotype coverage and compatibility with national testing algorithms while competing for highly centralized public tenders. Different countries also use different combinations of birth testing, six-week testing, breastfeeding follow-up and laboratory referral systems, which limits full standardization of demand forecasting and increases the importance of flexible product configurations and reliable distribution.

Industry Chain Analysis

The upstream portion of the HIV Early Infant Diagnosis Molecular Diagnostic Tests industry consists primarily of molecular biology enzymes, primers and probes, nucleic acid extraction chemistries, controls and calibrators, reaction plastics, cartridge components, membranes, packaging materials and specialized raw materials used in PCR and other nucleic acid amplification systems. Technical requirements are relatively high because assay sensitivity, contamination control, reagent stability and subtype inclusivity directly affect clinical performance. Proprietary cartridge designs and platform-specific reagent formulations can also create substantial supplier qualification and

validation requirements.

Midstream value creation is concentrated in assay development, reagent formulation, cartridge or kit manufacturing, filling and packaging, quality control, regulatory compliance and integration with proprietary molecular analyzers. Downstream demand comes mainly from national HIV programs, public-health laboratory networks, maternity and pediatric services, centralized molecular laboratories and decentralized point-of-care facilities. Economic value is created not only through analytical performance but also through faster result delivery, lower sample-handling burden, compatibility with dried blood spots or low-volume whole blood, reliable reagent supply and the ability to integrate EID into existing diagnostic infrastructure.

Segment Insights

By product type, the market exhibits a dual centralized and decentralized structure. Automated analyzer reagent kits remain important where national laboratory networks operate established high-throughput molecular systems, while integrated cartridge tests are particularly suited to near-patient deployment because they reduce manual processing and laboratory infrastructure requirements. Conventional PCR reagent kits retain a role in regional markets with existing real-time PCR capacity and more flexible laboratory workflows. Within detection targets, HIV DNA, HIV RNA and total nucleic acid approaches are all commercially established, reflecting differences in assay design rather than fundamentally different clinical objectives.

Qualitative testing remains the dominant design for dedicated EID assays because the core clinical question is whether infection is present, while appropriately validated quantitative NAT can also contribute to infant diagnosis. PCR-based NAT represents the broadest technology base among confirmed commercial products, whereas TMA and other isothermal amplification technologies provide differentiated alternatives. Product opportunity is increasingly linked to workflow efficiency and sample accessibility rather than amplification chemistry alone.

Downstream Market Opportunities

Routine initial EID at approximately four to six weeks or the earliest available opportunity remains the central programmatic application, while birth NAT is an important complementary use in higher-risk settings. Scheduled repeat testing after an initial negative result and confirmatory NAT after a positive test generate additional recurring reagent demand. Breastfeeding-related testing represents a particularly

important opportunity in high-burden regions because transmission risk persists while breastfeeding continues, requiring additional diagnostic follow-up beyond the first EID test. WHO guidance therefore treats infant diagnosis as a longitudinal testing pathway rather than a single diagnostic event.

Regional Insights

Sub-Saharan Africa represents the principal demand center for HIV Early Infant Diagnosis Molecular Diagnostic Tests because of the concentration of pediatric HIV exposure and national prevention-of-mother-to-child-transmission programs. Market maturity nevertheless varies significantly within the region. In 2024, EID coverage reached approximately 74% in eastern and southern Africa but only about 30% in western and central Africa, indicating substantial unmet testing potential in the latter region alongside greater financing and implementation constraints.

North America and Europe represent smaller-volume but technologically advanced markets characterized by stringent regulatory requirements and broad availability of automated NAT platforms. China and Russia add regional manufacturing diversity through domestic HIV DNA testing products, while other Asian markets remain comparatively smaller in absolute EID demand. Future regional expansion is therefore expected to depend less on broad geographic penetration and more on closing diagnostic coverage gaps in high-burden African markets and improving access to timely virological testing.

Competitive Landscape Analysis

The competitive landscape is concentrated because HIV EID requires validated molecular performance, regulated manufacturing and integration with established diagnostic infrastructure. Abbott Laboratories, Roche, Cepheid AB and Hologic, Inc. represent the large-scale multinational group, with competitive advantages derived from installed molecular platforms, regulatory coverage, global procurement experience and broad technical support capabilities. Daan Gene Co., Ltd. and the Central Research Institute of Epidemiology with its AmpliSens production system provide regional manufacturing depth, while Diagnostics for the Real World Ltd, Sacace Biotechnologies S.r.l. and Tianjin Genetic Biotek Co., Ltd. represent specialist or regional producers. Competition is differentiated by platform format: centralized suppliers emphasize throughput and laboratory consolidation, whereas cartridge-oriented systems emphasize faster decentralized access. Because procurement is concentrated in public-health programs, product reliability, supply continuity, platform availability and total

testing workflow are as important as nominal reagent price in supplier selection.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “HIV Early Infant Diagnosis Molecular Diagnostic Tests Industry Forecast” looks at past sales and reviews total world HIV Early Infant Diagnosis Molecular Diagnostic Tests sales in 2025, providing a comprehensive analysis by region and market sector of projected HIV Early Infant Diagnosis Molecular Diagnostic Tests sales for 2026 through 2032. With HIV Early Infant Diagnosis Molecular Diagnostic Tests sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world HIV Early Infant Diagnosis Molecular Diagnostic Tests industry.

This Insight Report provides a comprehensive analysis of the global HIV Early Infant Diagnosis Molecular Diagnostic Tests landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on HIV Early Infant Diagnosis Molecular Diagnostic Tests portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global HIV Early Infant Diagnosis Molecular Diagnostic Tests market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for HIV Early Infant Diagnosis Molecular Diagnostic Tests and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global HIV Early Infant Diagnosis Molecular Diagnostic Tests.

This report presents a comprehensive overview, market shares, and growth opportunities of HIV Early Infant Diagnosis Molecular Diagnostic Tests market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

Integrated Cartridge Tests

Automated Analyzer Reagent Kits

Conventional PCR Reagent Kits

Other

Segmentation by Target Nucleic Acid:

HIV DNA Tests

HIV RNA Tests

HIV Total Nucleic Acid Tests

Other

Segmentation by Application:

Birth NAT Testing

Routine Initial EID NAT Testing

Scheduled Repeat EID NAT Testing

Confirmatory EID NAT Testing

Breastfeeding-Related Additional NAT Testing

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Abbott Laboratories

Roche

Cepheid AB

Hologic, Inc.

Daan Gene Co., Ltd.

Federal Budget Institute of Science Central Research Institute of Epidemiology

Diagnostics for the Real World Ltd

Sacace Biotechnologies S.r.l.

Tianjin Genetic Biotek Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global HIV Early Infant Diagnosis Molecular Diagnostic Tests market?

What factors are driving HIV Early Infant Diagnosis Molecular Diagnostic Tests market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do HIV Early Infant Diagnosis Molecular Diagnostic Tests market opportunities vary by end market size?

How does HIV Early Infant Diagnosis Molecular Diagnostic Tests break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for HIV Early Infant Diagnosis Molecular Diagnostic Tests by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for HIV Early Infant Diagnosis Molecular Diagnostic Tests by Country/Region, 2021, 2025 & 2032

2.2 HIV Early Infant Diagnosis Molecular Diagnostic Tests Segment by Type

2.2.1 Integrated Cartridge Tests

2.2.2 Automated Analyzer Reagent Kits

2.2.3 Conventional PCR Reagent Kits

2.2.4 Other

2.2.5 HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type

2.2.5.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type (2021-2026)

2.2.5.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue and Market Share by Type (2021-2026)

2.2.5.3 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Type (2021-2026)

2.3 HIV Early Infant Diagnosis Molecular Diagnostic Tests Segment by Target Nucleic Acid

2.3.1 HIV DNA Tests

2.3.2 HIV RNA Tests

2.3.3 HIV Total Nucleic Acid Tests

2.3.4 Other

2.3.5 HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Target Nucleic Acid

2.3.5.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Target Nucleic Acid (2021-2026)

2.3.5.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue and Market Share by Target Nucleic Acid (2021-2026)

2.3.5.3 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Target Nucleic Acid (2021-2026)

2.4 HIV Early Infant Diagnosis Molecular Diagnostic Tests Segment by Application

2.4.1 Birth NAT Testing

2.4.2 Routine Initial EID NAT Testing

2.4.3 Scheduled Repeat EID NAT Testing

2.4.4 Confirmatory EID NAT Testing

2.4.5 Breastfeeding-Related Additional NAT Testing

2.4.6 Other

2.4.7 HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application

2.4.7.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Market Share by Application (2021-2026)

2.4.7.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue and Market Share by Application (2021-2026)

2.4.7.3 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Breakdown Data by Company

3.1.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Sales by Company (2021-2026)

3.1.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Company (2021-2026)

3.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Revenue by Company (2021-2026)

3.2.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Company (2021-2026)

3.2.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Company (2021-2026)

3.3 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by

Company

3.4 Key Manufacturers HIV Early Infant Diagnosis Molecular Diagnostic Tests

Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers HIV Early Infant Diagnosis Molecular Diagnostic Tests

Product Location Distribution

3.4.2 Players HIV Early Infant Diagnosis Molecular Diagnostic Tests Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HIV EARLY INFANT DIAGNOSIS MOLECULAR DIAGNOSTIC TESTS BY GEOGRAPHIC REGION

4.1 World Historic HIV Early Infant Diagnosis Molecular Diagnostic Tests Market Size by Geographic Region (2021-2026)

4.1.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Sales by Geographic Region (2021-2026)

4.1.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic HIV Early Infant Diagnosis Molecular Diagnostic Tests Market Size by Country/Region (2021-2026)

4.2.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Sales by Country/Region (2021-2026)

4.2.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Revenue by Country/Region (2021-2026)

4.3 Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Growth

4.4 APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Growth

4.5 Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Growth

4.6 Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Growth

5 AMERICAS

5.1 Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country

5.1.1 Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country (2021-2026)

5.1.2 Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by

Country (2021-2026)

5.2 Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026)

5.3 Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Region

6.1.1 APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Region (2021-2026)

6.1.2 APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Region (2021-2026)

6.2 APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026)

6.3 APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests by Country

7.1.1 Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country (2021-2026)

7.1.2 Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Country (2021-2026)

7.2 Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026)

7.3 Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application

(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests by Country

8.1.1 Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country (2021-2026)

8.1.2 Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Country (2021-2026)

8.2 Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026)

8.3 Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of HIV Early Infant Diagnosis Molecular Diagnostic Tests

10.3 Manufacturing Process Analysis of HIV Early Infant Diagnosis Molecular Diagnostic Tests

10.4 Industry Chain Structure of HIV Early Infant Diagnosis Molecular Diagnostic Tests

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 HIV Early Infant Diagnosis Molecular Diagnostic Tests Distributors

11.3 HIV Early Infant Diagnosis Molecular Diagnostic Tests Customer

12 WORLD FORECAST REVIEW FOR HIV EARLY INFANT DIAGNOSIS MOLECULAR DIAGNOSTIC TESTS BY GEOGRAPHIC REGION

12.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market Size Forecast by Region

12.1.1 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Forecast by Region (2027-2032)

12.1.2 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Forecast by Type (2027-2032)

12.7 Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Abbott Laboratories

13.1.1 Abbott Laboratories Company Information

13.1.2 Abbott Laboratories HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

13.1.3 Abbott Laboratories HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Abbott Laboratories Main Business Overview

13.1.5 Abbott Laboratories Latest Developments

13.2 Roche

13.2.1 Roche Company Information

13.2.2 Roche HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

13.2.3 Roche HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Roche Main Business Overview

13.2.5 Roche Latest Developments

13.3 Cepheid AB

13.3.1 Cepheid AB Company Information

13.3.2 Cepheid AB HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

13.3.3 Cepheid AB HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Cepheid AB Main Business Overview

13.3.5 Cepheid AB Latest Developments

13.4 Hologic, Inc.

13.4.1 Hologic, Inc. Company Information

13.4.2 Hologic, Inc. HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

13.4.3 Hologic, Inc. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Hologic, Inc. Main Business Overview

13.4.5 Hologic, Inc. Latest Developments

13.5 Daan Gene Co., Ltd.

13.5.1 Daan Gene Co., Ltd. Company Information

13.5.2 Daan Gene Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

13.5.3 Daan Gene Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Daan Gene Co., Ltd. Main Business Overview

13.5.5 Daan Gene Co., Ltd. Latest Developments

13.6 Federal Budget Institute of Science Central Research Institute of Epidemiology

13.6.1 Federal Budget Institute of Science Central Research Institute of Epidemiology Company Information

13.6.2 Federal Budget Institute of Science Central Research Institute of Epidemiology HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

13.6.3 Federal Budget Institute of Science Central Research Institute of Epidemiology HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Federal Budget Institute of Science Central Research Institute of Epidemiology
Main Business Overview

13.6.5 Federal Budget Institute of Science Central Research Institute of Epidemiology
Latest Developments

13.7 Diagnostics for the Real World Ltd

13.7.1 Diagnostics for the Real World Ltd Company Information

13.7.2 Diagnostics for the Real World Ltd HIV Early Infant Diagnosis Molecular
Diagnostic Tests Product Portfolios and Specifications

13.7.3 Diagnostics for the Real World Ltd HIV Early Infant Diagnosis Molecular
Diagnostic Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Diagnostics for the Real World Ltd Main Business Overview

13.7.5 Diagnostics for the Real World Ltd Latest Developments

13.8 Sacace Biotechnologies S.r.l.

13.8.1 Sacace Biotechnologies S.r.l. Company Information

13.8.2 Sacace Biotechnologies S.r.l. HIV Early Infant Diagnosis Molecular Diagnostic
Tests Product Portfolios and Specifications

13.8.3 Sacace Biotechnologies S.r.l. HIV Early Infant Diagnosis Molecular Diagnostic
Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Sacace Biotechnologies S.r.l. Main Business Overview

13.8.5 Sacace Biotechnologies S.r.l. Latest Developments

13.9 Tianjin Genetic Biotek Co., Ltd.

13.9.1 Tianjin Genetic Biotek Co., Ltd. Company Information

13.9.2 Tianjin Genetic Biotek Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic
Tests Product Portfolios and Specifications

13.9.3 Tianjin Genetic Biotek Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic
Tests Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Tianjin Genetic Biotek Co., Ltd. Main Business Overview

13.9.5 Tianjin Genetic Biotek Co., Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Integrated Cartridge Tests
- Table 4. Major Players of Automated Analyzer Reagent Kits
- Table 5. Major Players of Conventional PCR Reagent Kits
- Table 6. Major Players of Other
- Table 7. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026) & (Units)
- Table 8. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type (2021-2026)
- Table 9. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Type (2021-2026) & (\$ million)
- Table 10. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Type (2021-2026)
- Table 11. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 12. Major Players of HIV DNA Tests
- Table 13. Major Players of HIV RNA Tests
- Table 14. Major Players of HIV Total Nucleic Acid Tests
- Table 15. Major Players of Other
- Table 16. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Target Nucleic Acid (2021-2026) & (Units)
- Table 17. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Target Nucleic Acid (2021-2026)
- Table 18. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Target Nucleic Acid (2021-2026) & (\$ million)
- Table 19. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Target Nucleic Acid (2021-2026)
- Table 20. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Target Nucleic Acid (2021-2026) & (US\$/Unit)
- Table 21. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale by Application (2021-2026) & (Units)
- Table 22. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Market

Share by Application (2021-2026)

Table 23. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Application (2021-2026) & (\$ million)

Table 24. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Application (2021-2026)

Table 25. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Application (2021-2026) & (US\$/Unit)

Table 26. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Company (2021-2026) & (Units)

Table 27. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Company (2021-2026)

Table 28. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Company (2021-2026) & (\$ millions)

Table 29. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Company (2021-2026)

Table 30. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Price by Company (2021-2026) & (US\$/Unit)

Table 31. Key Manufacturers HIV Early Infant Diagnosis Molecular Diagnostic Tests Producing Area Distribution and Sales Area

Table 32. Players HIV Early Infant Diagnosis Molecular Diagnostic Tests Products Offered

Table 33. HIV Early Infant Diagnosis Molecular Diagnostic Tests Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 34. New Products and Potential Entrants

Table 35. Market M&A Activity & Strategy

Table 36. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Geographic Region (2021-2026) & (Units)

Table 37. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share Geographic Region (2021-2026)

Table 38. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 39. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Geographic Region (2021-2026)

Table 40. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country/Region (2021-2026) & (Units)

Table 41. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country/Region (2021-2026)

Table 42. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Country/Region (2021-2026) & (\$ millions)

Table 43. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Country/Region (2021-2026)

Table 44. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country (2021-2026) & (Units)

Table 45. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country (2021-2026)

Table 46. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Country (2021-2026) & (\$ millions)

Table 47. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026) & (Units)

Table 48. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026) & (Units)

Table 49. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Region (2021-2026) & (Units)

Table 50. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Region (2021-2026)

Table 51. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Region (2021-2026) & (\$ millions)

Table 52. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026) & (Units)

Table 53. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026) & (Units)

Table 54. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country (2021-2026) & (Units)

Table 55. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Country (2021-2026) & (\$ millions)

Table 56. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026) & (Units)

Table 57. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026) & (Units)

Table 58. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Country (2021-2026) & (Units)

Table 59. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Country (2021-2026)

Table 60. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Type (2021-2026) & (Units)

Table 61. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Application (2021-2026) & (Units)

Table 62. Key Market Drivers & Growth Opportunities of HIV Early Infant Diagnosis

Molecular Diagnostic Tests

Table 63. Key Market Challenges & Risks of HIV Early Infant Diagnosis Molecular Diagnostic Tests

Table 64. Key Industry Trends of HIV Early Infant Diagnosis Molecular Diagnostic Tests

Table 65. HIV Early Infant Diagnosis Molecular Diagnostic Tests Raw Material

Table 66. Key Suppliers of Raw Materials

Table 67. HIV Early Infant Diagnosis Molecular Diagnostic Tests Distributors List

Table 68. HIV Early Infant Diagnosis Molecular Diagnostic Tests Customer List

Table 69. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Region (2027-2032) & (Units)

Table 70. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 71. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Country (2027-2032) & (Units)

Table 72. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 73. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Region (2027-2032) & (Units)

Table 74. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 75. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Country (2027-2032) & (Units)

Table 76. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 77. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Country (2027-2032) & (Units)

Table 78. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 79. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Type (2027-2032) & (Units)

Table 80. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 81. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Forecast by Application (2027-2032) & (Units)

Table 82. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 83. Abbott Laboratories Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 84. Abbott Laboratories HIV Early Infant Diagnosis Molecular Diagnostic Tests

Product Portfolios and Specifications

Table 85. Abbott Laboratories HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 86. Abbott Laboratories Main Business

Table 87. Abbott Laboratories Latest Developments

Table 88. Roche Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 89. Roche HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 90. Roche HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 91. Roche Main Business

Table 92. Roche Latest Developments

Table 93. Cepheid AB Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 94. Cepheid AB HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 95. Cepheid AB HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 96. Cepheid AB Main Business

Table 97. Cepheid AB Latest Developments

Table 98. Hologic, Inc. Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 99. Hologic, Inc. HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 100. Hologic, Inc. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 101. Hologic, Inc. Main Business

Table 102. Hologic, Inc. Latest Developments

Table 103. Daan Gene Co., Ltd. Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 104. Daan Gene Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 105. Daan Gene Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 106. Daan Gene Co., Ltd. Main Business

Table 107. Daan Gene Co., Ltd. Latest Developments

Table 108. Federal Budget Institute of Science Central Research Institute of Epidemiology Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests

Manufacturing Base, Sales Area and Its Competitors

Table 109. Federal Budget Institute of Science Central Research Institute of Epidemiology HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 110. Federal Budget Institute of Science Central Research Institute of Epidemiology HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 111. Federal Budget Institute of Science Central Research Institute of Epidemiology Main Business

Table 112. Federal Budget Institute of Science Central Research Institute of Epidemiology Latest Developments

Table 113. Diagnostics for the Real World Ltd Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 114. Diagnostics for the Real World Ltd HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 115. Diagnostics for the Real World Ltd HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 116. Diagnostics for the Real World Ltd Main Business

Table 117. Diagnostics for the Real World Ltd Latest Developments

Table 118. Sacace Biotechnologies S.r.l. Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 119. Sacace Biotechnologies S.r.l. HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 120. Sacace Biotechnologies S.r.l. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 121. Sacace Biotechnologies S.r.l. Main Business

Table 122. Sacace Biotechnologies S.r.l. Latest Developments

Table 123. Tianjin Genetic Biotek Co., Ltd. Basic Information, HIV Early Infant Diagnosis Molecular Diagnostic Tests Manufacturing Base, Sales Area and Its Competitors

Table 124. Tianjin Genetic Biotek Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic Tests Product Portfolios and Specifications

Table 125. Tianjin Genetic Biotek Co., Ltd. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales (Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 126. Tianjin Genetic Biotek Co., Ltd. Main Business

Table 127. Tianjin Genetic Biotek Co., Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of HIV Early Infant Diagnosis Molecular Diagnostic Tests

Figure 2. HIV Early Infant Diagnosis Molecular Diagnostic Tests Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Growth Rate 2021-2032 (Units)

Figure 7. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country/Region (2025)

Figure 10. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Integrated Cartridge Tests

Figure 12. Product Picture of Automated Analyzer Reagent Kits

Figure 13. Product Picture of Conventional PCR Reagent Kits

Figure 14. Product Picture of Other

Figure 15. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type in 2026

Figure 16. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Type (2021-2026)

Figure 17. Product Picture of HIV DNA Tests

Figure 18. Product Picture of HIV RNA Tests

Figure 19. Product Picture of HIV Total Nucleic Acid Tests

Figure 20. Product Picture of Other

Figure 21. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Target Nucleic Acid in 2026

Figure 22. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Target Nucleic Acid (2021-2026)

Figure 23. HIV Early Infant Diagnosis Molecular Diagnostic Tests Consumed in Birth NAT Testing

Figure 24. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market: Birth

NAT Testing (2021-2026) & (Units)

Figure 25. HIV Early Infant Diagnosis Molecular Diagnostic Tests Consumed in Routine Initial EID NAT Testing

Figure 26. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market: Routine Initial EID NAT Testing (2021-2026) & (Units)

Figure 27. HIV Early Infant Diagnosis Molecular Diagnostic Tests Consumed in Scheduled Repeat EID NAT Testing

Figure 28. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market: Scheduled Repeat EID NAT Testing (2021-2026) & (Units)

Figure 29. HIV Early Infant Diagnosis Molecular Diagnostic Tests Consumed in Confirmatory EID NAT Testing

Figure 30. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market: Confirmatory EID NAT Testing (2021-2026) & (Units)

Figure 31. HIV Early Infant Diagnosis Molecular Diagnostic Tests Consumed in Breastfeeding-Related Additional NAT Testing

Figure 32. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market: Breastfeeding-Related Additional NAT Testing (2021-2026) & (Units)

Figure 33. HIV Early Infant Diagnosis Molecular Diagnostic Tests Consumed in Other

Figure 34. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market: Other (2021-2026) & (Units)

Figure 35. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sale Market Share by Application (2025)

Figure 36. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Application in 2025

Figure 37. HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales by Company in 2025 (Units)

Figure 38. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Company in 2025

Figure 39. HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue by Company in 2025 (\$ millions)

Figure 40. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Company in 2025

Figure 41. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Geographic Region (2021-2026)

Figure 42. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Geographic Region in 2025

Figure 43. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales 2021-2026 (Units)

Figure 44. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue

2021-2026 (\$ millions)

Figure 45. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales

2021-2026 (Units)

Figure 46. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue

2021-2026 (\$ millions)

Figure 47. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales

2021-2026 (Units)

Figure 48. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue

2021-2026 (\$ millions)

Figure 49. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales 2021-2026 (Units)

Figure 50. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue 2021-2026 (\$ millions)

Figure 51. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country in 2025

Figure 52. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Country (2021-2026)

Figure 53. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type (2021-2026)

Figure 54. Americas HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Application (2021-2026)

Figure 55. United States HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 56. Canada HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 57. Mexico HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 58. Brazil HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 59. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Region in 2025

Figure 60. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Region (2021-2026)

Figure 61. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type (2021-2026)

Figure 62. APAC HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Application (2021-2026)

Figure 63. China HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 64. Japan HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 65. South Korea HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 66. Southeast Asia HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 67. India HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 68. Australia HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 69. China Taiwan HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 70. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country in 2025

Figure 71. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share by Country (2021-2026)

Figure 72. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type (2021-2026)

Figure 73. Europe HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Application (2021-2026)

Figure 74. Germany HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 75. France HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 76. UK HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 77. Italy HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 78. Russia HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 79. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Country (2021-2026)

Figure 80. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Type (2021-2026)

Figure 81. Middle East & Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share by Application (2021-2026)

Figure 82. Egypt HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 83. South Africa HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue

Growth 2021-2026 (\$ millions)

Figure 84. Israel HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue

Growth 2021-2026 (\$ millions)

Figure 85. Turkey HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue

Growth 2021-2026 (\$ millions)

Figure 86. GCC Countries HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Growth 2021-2026 (\$ millions)

Figure 87. Manufacturing Cost Structure Analysis of HIV Early Infant Diagnosis Molecular Diagnostic Tests in 2026

Figure 88. Manufacturing Process Analysis of HIV Early Infant Diagnosis Molecular Diagnostic Tests

Figure 89. Industry Chain Structure of HIV Early Infant Diagnosis Molecular Diagnostic Tests

Figure 90. Channels of Distribution

Figure 91. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Forecast by Region (2027-2032)

Figure 92. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share Forecast by Region (2027-2032)

Figure 93. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share Forecast by Type (2027-2032)

Figure 94. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share Forecast by Type (2027-2032)

Figure 95. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Sales Market Share Forecast by Application (2027-2032)

Figure 96. Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global HIV Early Infant Diagnosis Molecular Diagnostic Tests Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GE3A0A7E0374EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE3A0A7E0374EN.html>